Wed.Oct 02, 2024

article thumbnail

Was Missouri’s bird flu case a one-off or something more? Quest for answers faces testing delay

STAT

U.S. health officials have run into obstacles in their efforts to determine whether a Missouri person infected with H5N1 bird flu passed the virus on to others, causing a delay that will likely fuel concerns about the possibility that there has been human-to-human transmission. The Centers for Disease Control and Prevention has blood samples from several health workers and a household contact of the Missouri case that it plans to test for antibodies that would indicate whether they too had been

363
363
article thumbnail

Kailera Therapeutics emerges from stealth with $400M for obesity drugs

PharmaVoice

The official launch comes five months after a filing indicated major investors such as Atlas Venture and Bain Capital were backing the biotech, then named “Hercules CM NewCo.

130
130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Why a map of a fruit fly’s brain has neuroscientists ‘blown away’

STAT

Mapping the brain is a daunting task because it contains a huge number of cells and cell connections. It took almost 50 labs around the world to create a new neural map, or connectome, of an adult fruit fly — the largest map of its kind, and an effort that will allow researchers to better understand the brain’s inner workings. Access to the full connectome, as published Wednesday in a series of papers in Nature , could represent a new era for neuroscience, according to some re

358
358
article thumbnail

How Roche plans to fill a projected $8B sales gap

PharmaVoice

Biosimilar competition will erode billions from the pharma giant’s bottom line in the next few years.

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

STAT+: After Cassava Alzheimer’s drug fiasco, the FDA must intervene to protect patients

STAT

For nearly a year, my stance on Cassava Sciences and its Alzheimer’s disease drug candidate simufilam has been clear: Emerging evidence shows the drug is inert, and patients with Alzheimer’s were misled into participating in ongoing Phase 3 clinical trials, so therefore, the Food and Drug Administration must take immediate steps to protect these vulnerable people from further harm.

356
356
article thumbnail

Amgen to face investor lawsuit over $10.7bn tax liability disclosure

pharmaphorum

A federal judge in New York has ruled that Amgen must answer to claims of misleading investors about billions owed to US tax authorities, allowing a securities-fraud class action to proceed against the pharmaceutical giant.

121
121

More Trending

article thumbnail

Exscientia outline robot and AI use in drug discovery workflow

Pharmaceutical Technology

Exscientia detailed how its robotics lab in Oxfordshire, UK is increasing productivity and efficiency in developing new molecules at ELRIG 2024.

110
110
article thumbnail

STAT+: CVS could break itself up. Why, and what does that mean for you?

STAT

Blame the pickleball paddles. Over the past year, CVS has made a concerted push to court seniors to enroll in its Aetna Medicare programs by offering free sports equipment, fishing rods, and other enticements. It worked maybe a little too well for CVS, as the surge in new customers backfired when the medical costs for those sporty seniors spiraled well beyond the company’s expectations.

article thumbnail

Insilico Medicine reports positive results for idiopathic pulmonary fibrosis therapy

Pharma Times

ISM001-055 shows promise in improving lung function among patients

147
147
article thumbnail

Opinion: When should marijuana use deny a patient an organ transplant?

STAT

In 2023, Kentucky became the most recent state to pass a law prohibiting the denial of organ transplantation to patients solely because of their marijuana use. The legislation is scheduled to go into effect Jan. 1, 2025. Over the past 11 years, similar measures have been enacted in 21 other states. Though these laws overstep into medical decision-making, they are part of a rising trend.

Hospitals 298
article thumbnail

Why Every Small Business Needs an HCM Solution: A Comprehensive Guide

Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.

article thumbnail

Episode 962: What Antibiotics Are Best At Toxin Inhibition?

Pharmacy Joe

In this episode, I’ll discuss the antibiotics that inhibit bacterial toxin production. Episode 962: What Antibiotics Are Best At Toxin Inhibition? Subscribe on iTunes , Android , or Stitcher Some bacteria produce microbial toxins that significantly contribute to infection severity. Notable examples include Clostridioides difficile, Staphylococcus aureus, and Streptococcus pyogenes.

article thumbnail

STAT+: Gilead strikes voluntary licensing deals in poor countries for its pricey HIV drug

STAT

In response to increased criticism of its pricing, Gilead Sciences has reached voluntary licensing deals with companies to make generic versions of its twice-yearly HIV medicine, lenacapavir, in 120 mostly low- and lower-middle-income countries. The move comes after a pair of late-stage clinical trials found the injectable medicine was highly effective in preventing HIV, paving the way for the company to seek regulatory approval for pre-exposure prophylaxis, or PrEP.

article thumbnail

Pharma Plant Sleuthing: 8 Ways to Find Manufacturing Capacity as an Outsider

Drug Patent Watch

As an outsider, finding out the manufacturing capacity of a given pharmaceutical manufacturing plant can be challenging due to the proprietary nature of such information. However, you can employ several strategies to gather relevant data: Example: Pfizer’s 2022 Annual Report states, “Our manufacturing facilities are located in 39 countries across 6 continents.

article thumbnail

STAT+: ResMed CEO on how wearables, GLP-1s will impact sleep apnea device sales

STAT

NEW YORK — The morning after presenting an upbeat outlook to analysts in a gilded hall in the New York Stock Exchange building, Mick Farrell, the CEO of ResMed, looked refreshed, despite a post-presentation cocktail reception. If the sleep tech magnate could have used more shuteye, he didn’t show it. Farrell leaned forward enthusiastically to inspect data from a reporter’s Apple smartwatch showing that it hadn’t detected signs of sleep apnea.

277
277
article thumbnail

Best Practices to Streamline Compensation Management: A Foundation for Growth

Speaker: Joe Sharpe and James Carlson

Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.

article thumbnail

Compliance, competition could be speed breakers

Express Pharma

Speaking at the recent ASSOCHAM Annual Pharma Summit 2024, Secretary, Department of Pharmaceuticals, Dr Arunish Chawla’s review of the regulatory reforms needs to go hand in hand with the growth opportunities. But lost among the headlines that 50 greenfield pharma plants would be completed in the next two years under the PLI scheme, and pharma and medtech becoming India’s fourth largest sector for merchandise exports, Dr Chawla’s comment that “we want to make India not just a pharmacy of the wor

article thumbnail

STAT+: Lawmakers want FTC to probe big PBMs over private-label biosimilar deals

STAT

A pair of U.S. lawmakers is urging the Federal Trade Commission to investigate the parent companies of two large pharmacy benefit managers over concerns that new business units might unfairly steer patients toward higher-cost medicines. The effort comes after CVS Health and Cigna — which own CVS Caremark and Express Scripts, respectively — launched subsidiaries that are striking “co-manufacturing” deals with companies that make biologic medicines and lower-cost versio

Labelling 276
article thumbnail

How Roche plans to fill a projected $8B sales gap

BioPharma Dive

Biosimilar competition to aging blockbusters will erode a large chunk of the pharma giant’s top line over the next few years.

article thumbnail

STAT+: Humana tumbles as insurer faces $3 billion hit to revenue over lower Medicare star ratings

STAT

Humana’s Medicare business has taken a financial beating all year, and it’s only going to get worse.

324
324
article thumbnail

Enhance Healthcare Efficiency With Top Payroll & HCM Services

Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.

article thumbnail

Gilead Sciences signs licencing agreements with six companies to manufacture, commercialise Lenacapavir

Express Pharma

Gilead Sciences Ireland UC has signed non-exclusive, royalty-free voluntary licensing agreements with six pharmaceutical manufacturers to make and sell generic lenacapavir, subject to required regulatory approvals, in 120 high-incidence, resource-limited countries, which are primarily low- and lower-middle income countries. The agreements were signed in advance of any global regulatory submissions to enable these countries to quickly introduce generic versions of lenacapavir for HIV prevention i

article thumbnail

Lilly invests $4.5 billion in a new research hub

STAT

This story first appeared in The Readout newsletter.  Sign up for The Readout  and receive STAT’s award-winning biotech news delivered straight to your inbox.  Good morning. Today, we look at the biggest biotech events to watch this quarter. And as my editor had to remind me (since I’m still in denial), we are indeed in the fourth quarter now.

article thumbnail

LoQus23 secures $43m to advance Huntington’s Disease therapy

Pharmaceutical Technology

The funds will support the development of LoQus23’s lead candidate, its MutSβ inhibitor, as it enters clinical development.

105
105
article thumbnail

STAT+: The biotech scorecard for the fourth quarter: 14 stock-moving events to watch

STAT

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the fourth quarter: Rarely before has a large-cap biotech had so much riding on the outcome of a Phase 2 study as Amgen does with its obesity treatment MariTide , also known as AMG 133. Results are coming before the end of the year. Novo Nordisk will report results of a Phase 3 study involving its obesity drug candidate CagriSema before the end of this year.

250
250
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Blue Shield of California bypasses PBMs to slash Humira prices by 90%

pharmaphorum

In a bold move to tackle soaring drug costs, Blue Shield of California is pioneering a strategy that bypasses traditional pharmacy benefit managers to slash the cost of Humira by 90%

97
article thumbnail

STAT+: Pharmalittle: We’re reading about a Blue Cross California deal for Humira, Gilead licensing an HIV drug, and more

STAT

Hello, everyone, and how are you today? We are doing just fine, thank you, especially since the middle of the week is upon us. After all, we have made it this far, so we are determined to hang on for another couple of days. And why not? The alternatives — at least those we can identify — are not so appetizing. And what better way to make the time fly than to keep busy.

article thumbnail

Review bodies asked to make earlier decision on NHS and GP pay for 2025/26

The Pharmacist

The government has asked the independent review bodies to deliver their recommendations on NHS and general practice pay ‘at the earlier point’ to help speed up pay awards for the next financial year. Health and social care secretary Wes Streeting has this week sent letters to the NHS Pay Review Body (NHSPRB) and the Review […] The post Review bodies asked to make earlier decision on NHS and GP pay for 2025/26 appeared first on The Pharmacist.

86
article thumbnail

Closed and Collaborative: Mergers, acquisitions, and partnerships in August 2024

pharmaphorum

Explore the mergers, acquisitions, and partnerships in August 2024. Discover how these collaborations are shaping the business landscape.

108
108
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

ARRS linked to reduced prescribing, study suggests

The Pharmacist

GP practices with more staff employed through the additional roles reimbursement scheme (ARRS), including pharmacists, have 'lower' prescribing rates, a study has suggested. Published in the British Journal of GPs (BJGP), The effects of ARRS staff in England on prescription patterns and patient satisfaction, found that the hiring of ARRS staff was ‘significantly associated’ with lower […] The post ARRS linked to reduced prescribing, study suggests appeared first on The Pharmacist.

85
article thumbnail

AlzeCure’s ACD856’s effects to be presented at Alzheimer’s conference

Pharma Times

Preclinical data on NeuroRestore therapy to be showcased at CTAD in Madrid

118
118
article thumbnail

The patient will see you now: Why embracing discomfort could transform patient engagement

pharmaphorum

The patient will see you now: Why embracing discomfort could transform patient engagement Mike.

114
114
article thumbnail

Genentech gains rights to next-generation CDK inhibitor medicines

European Pharmaceutical Review

Genentech (a member of the Roche Group) has agreed to acquire next-generation CDK inhibitors for breast cancer from Regor Pharmaceuticals for $850 million. Regor is eligible for further payments dependent on whether certain development, regulatory and commercial milestones are met. Genentech is responsible for clinical development, manufacturing and commercialisation globally. “Genentech is well-positioned to bring these novel therapeutics to their full potential,” commented Xiayang

article thumbnail

Revisionist history on healthcare at the VP debate

pharmaphorum

In the VP debate, Tim Walz and JD Vance were forceful, unexpectedly convivial, and fast and loose with the facts, particularly on healthcare.

99